Novartis expects low single-digit decline in 2026 operating profit

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/20/2026

1. BA
2. SPY
3. USO
4. XFLT
5. EVEX
6. AMC
7. GE
8. RTX
9. DPZ
10. NVDA

February 4, 2026 1:37 AM EST

FILE PHOTO: The logo of Swiss drugmaker Novartis is pictured at the company's French headquarters in Rueil-Malmaison near Paris, France, April 22, 2020. REUTERS/Charles Platiau/File Photo

FRANKFURT, Feb ⁠4 (Reuters) - Swiss ⁠drugmaker ‍Novartis forecast a decline in 2026 operating profit in ‍the low single-digit percentage range on ​Wednesday, held back by competition from ​cheaper copies of established products such as heart drug Entresto.

It also reported a 1% gain ​in fourth-quarter operating profit, which is adjusted for special items, ​on higher sales of breast cancer drug Kisqali, multiple ‌sclerosis drug Kesimpta and psoriasis drug Cosentyx, among other drugs.

The ​profit figure came in ⁠at $4.92 billion, in line with an analyst consensus of ‌about $4.9 billion, compiled by Visible Alpha.

Novartis is leaning on fast-growing cancer drugs ‌Kisqali and Scemblix and its $30 billion acquisition ‌and licensing push last year to address the impending patent cliff for some of ‍its blockbuster drugs, including Entresto for heart failure, allergy ⁠shot Xolair and Cosentyx.

(Reporting by Ludwig Burger in Frankfurt and Bhanvi Satija in London; Editing by Emelia Sithole-Matarise and Linda Pasquini)


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Reuters

Related Entities

Definitive Agreement